Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer
- 1 November 2001
- journal article
- clinical trial
- Published by Elsevier BV in Annals of Oncology
- Vol. 12 (11), 1545-1551
- https://doi.org/10.1023/a:1013184301155
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancerBritish Journal of Cancer, 1999
- Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.Journal of Clinical Oncology, 1998
- Relationship of Mitotic Arrest and Apoptosis to Antitumor Effect of PaclitaxelJNCI Journal of the National Cancer Institute, 1996
- In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 productBritish Journal of Cancer, 1996
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.Journal of Clinical Oncology, 1996
- A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclinesEuropean Journal Of Cancer, 1996
- The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A reviewGene, 1995
- Humanization of an anti-p185HER2 antibody for human cancer therapy.Proceedings of the National Academy of Sciences of the United States of America, 1992
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 1991
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985